New drug treatment for heart failure

Date Published: 
Friday, September 28, 2018

Professor Rob Doughty talks about a combination medicine for the management of congestive heart failure - ‘Entresto’ sacubitril/ valsartan. Rob is a cardiologist and holds the Heart Foundation Chair in Heart Health at the University of Auckland. He practices at Auckland City Hospital where he is the leader of the heart failure service and privately at the Auckland Heart group.




  • Introduction to this drug ‘Entresto’ Sacubitril/ Valsartan
  • What is a neprilysin inhibitor? What is its mechanism of action?
  • What is so special about the combination medicine?
  • What patients should we consider using Entresto in? Where does it fit in the treatment ladder?
  • What are the benefits to our patients of using this medication?
  • What is the starting dose and how is it titrated?
  • Are there populations that need to be started more slowly?
  • What other considerations (paediatrics, pregnant or breastfeeding women)?
  • Red flags for urgent referral
  • Side effects to warn patients about
  • Drug interactions to be aware of


Take home messages

  • Entresto is a medication for the treatment of patients with symptomatic heart failure with reduced ejection fraction.
  • It requires careful consideration in terms of dose introduction, titration and monitoring.
  • There are many important interactions and multiple common side effects- be aware of these and provide the patient with a consumer medicine information sheet.
  • If angioedema is suspected- stop the medicine immediately and speak to a cardiologist.




Rob Doughty

To contact Rob Click here.

Episode supported by:


Recognition of Learning Activities

Don't forget to log your time with The Royal New Zealand College of General Practitioners portal for recognition of learning activities.

RNZCGP website

This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.